Welcome to our dedicated page for Elutia SEC filings (Ticker: ELUT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Elutia Inc. filings document the regulatory record for a medical technology company developing and commercializing drug-eluting biomatrix products. Form 8-K reports cover financial results, preliminary operating updates, Nasdaq listing notices and compliance events, and material compensation actions tied to the company's Class A common stock.
Proxy materials disclose board matters, executive compensation, equity-award information, shareholder voting items, and governance practices. The filing record also includes disclosures on inducement award plans, stock-based compensation capacity, registered securities on the Nasdaq Capital Market, and emerging growth company status.
Matthew Ferguson, Chief Financial Officer of Elutia Inc. (ELUT), reported insider transactions dated 09/10/2025. On that date he received 29,000 shares of Class A Common Stock upon vesting of restricted stock units, which increased his beneficial ownership to 379,417 shares. The filing also shows 10,348 shares were withheld to satisfy tax withholding at a reported price of $1.36, reducing the reported holding to 369,069 shares. The filing discloses the original RSU grants made on January 31, 2024 (150,000 and 50,000 RSUs) and the vesting schedules for those grants. The form is signed by Mr. Ferguson on 09/11/2025.
C. Randal Mills, who serves as President, Chief Executive Officer and a director of Elutia Inc. (ELUT), reported the vesting of 27,083 restricted stock units (RSUs) on 09/10/2025. Those vested RSUs converted into Class A common stock and are reported as an acquisition. The issuer withheld 9,664 shares to satisfy tax withholding at an indicated withholding price of $1.36 per share.
Following these transactions the filing shows the reporting person beneficially owning 338,586 shares of Class A common stock. The filing also discloses that on January 31, 2024 the reporting person was granted 487,500 RSUs, of which 297,916 RSUs are shown as derivative securities still outstanding and subject to the vesting schedule described in the filing.
Elutia Inc. agreed to sell substantially all assets of its cardiac implantable electronic device (CIED) business, including CanGaroo, EluPro and related envelope products, to Boston Scientific Corporation and Cardiac Pacemakers Inc. for up to $88 million in cash. The price includes $80 million payable at closing and $8 million held in escrow for twelve months as an indemnity holdback.
The CIED assets comprise substantially all assets in Elutia’s Device Protection segment. Closing is subject to customary conditions, including required consents, no prohibitive laws or orders, no material adverse effect on the CIED business, and transfer of employees, and is expected in the fourth quarter of 2025.
Elutia agreed to five-year non‑competition restrictions in business lines related to the current CIED business and entered into customary mutual indemnification arrangements allocating liabilities between the parties for pre‑ and post‑closing periods and specified excluded assets and liabilities.
Elutia Inc. disclosed that it entered into a Fifth Amendment to the Credit Agreement dated August 14, 2025 among Elutia Inc., SWK Funding LLC (as Agent) and the lenders party thereto. The 8-K lists this amendment as an exhibit (Exhibit 10.1) and cites Items 1.01 (entry into a material definitive agreement) and 2.03 (creation of a direct financial obligation or off-balance-sheet arrangement). The filing includes an Inline XBRL cover page (Exhibit 104). The document provides the existence and date of the amendment but does not disclose the amendment's terms, financial amounts, covenants, maturity changes, or other transactional details.
Elutia, Inc. reported continued operating losses and significant legal and liquidity risks in its Form 10-Q. For the six months ended June 30, 2025, the company recorded a net loss of $13.5 million and an accumulated deficit of $243.1 million. Cash used in operations totaled $17.1 million year-to-date and the company expects ongoing cash outflows for the rest of 2025, raising concerns about its ability to achieve and sustain profitability.
The company completed the sale of its Orthobiologics Business (initial gain recognized of $6.0 million in 2023 and an additional $0.2 million in 2024) with potential earn-outs of up to $20 million and a $1.5 million indemnity holdback. Material litigation includes extensive FiberCel and VBM claims: the company recorded $13.3 million as a probable liability for 47 FiberCel cases and $3.7 million for VBM-related matters, with substantial settlements already paid and insurance receivables recorded. Elutia has a secured SWK loan facility with a weighted average interest rate of 12.6% for the three months ended June 30, 2025 and amended covenants requiring a minimum liquidity of $8.0 million. The company discloses substantial risks around commercialization of EluPro, supplier dependence, indemnities and contingent liabilities.
Elutia Inc. furnished an update on its business by submitting a Form 8‑K that includes a press release announcing its financial results for the second quarter ended June 30, 2025. The press release is provided as Exhibit 99.1 and is incorporated by reference into this report. Elutia’s Class A common stock trades on the Nasdaq Capital Market under the symbol ELUT, and the company is identified as an emerging growth company under applicable SEC rules.
Form 4 overview: On 06/21/2025 Elutia Inc. (ELUT) filed a Form 4 detailing equity activity by President & CEO C. Randal Mills, who is also a director.
Transactions:
- 22,473 Class A shares were acquired through the vesting and settlement of an equal number of restricted stock units (RSUs) (Code “M”).
- 8,019 shares were withheld at $1.81 per share to satisfy tax obligations (Code “F”).
The net increase to the executive’s direct holdings is 14,454 shares.
Post-transaction ownership: Mills now directly owns 321,167 Class A shares. Table II shows 22,473 RSUs still outstanding, indicating additional shares may be delivered in future periods.
Award background: The underlying RSU grant was issued on 06/21/2022 for 89,893 units, vesting in four equal annual tranches beginning 06/21/2023. The current filing represents the second scheduled vesting installment.
No open-market purchases or sales occurred, and the form does not cite a Rule 10b5-1 plan. As such, the disclosure reflects a routine insider vesting event with limited immediate market impact for investors.